You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Exon 20 insertion

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

NSCLC, NSCLC, EGFR/HER2 Exon 20 Insertion Mutation Trial in Fairfax (STX-721)

Not yet recruiting
  • Non-Small Cell Lung Cancer
  • +2 more
  • Fairfax, Virginia
    NEXT Virginia
Sep 18, 2023

Advanced or Metastatic NSCLS With Exon 20 Insertion Mutation Trial in Canton (TAS6417)

Recruiting
  • Advanced or Metastatic NSCLS With Exon 20 Insertion Mutation
  • Canton, Ohio
    Gabrail Cancer and Research Center
Jul 25, 2023

NSCLC Trial in Shanghai (Furmonertinib 160mg, Furmonertinib 240mg)

Recruiting
  • NSCLC
  • Furmonertinib 160mg
  • Furmonertinib 240mg
  • Shanghai, China
    Shanghai Chest hospital
Jan 16, 2023

Advanced or Metastatic NSCLC Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations Trial in

Recruiting
  • Advanced or Metastatic NSCLC Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations
  • Canton, Ohio
    Gabrail Cancer and Research Center
Jul 21, 2023

NSCLC Trial (Mobocertinib 160 mg)

Approved for marketing
  • Carcinoma, Non-Small-Cell Lung
  • Mobocertinib 160 mg
  • (no location specified)
Sep 28, 2022

NSCLC Trial (Furmonertinib)

Not yet recruiting
  • NSCLC
  • (no location specified)
Jul 17, 2022

Lung Tumor Malignant, NSCLC, Respiratory Tract Tumors Trial in United States (BLU-451)

Recruiting
  • Lung Neoplasm Malignant
  • +18 more
  • Fairfax, Virginia
    New Experimental Therapeutics of Virginia (NEXT Oncology)
Mar 29, 2022

Mobocertinib in Adults With Lung Cancer in China (MEANING)

Not yet recruiting
  • Non-small Cell Lung Cancer (NSCLC)
  • No Intervention
  • Shanghai, China
    Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai J
May 9, 2023

Non-squamous NSCLC Trial (biological, drug, dietary supplement)

Not yet recruiting
  • Non-squamous NSCLC
  • Pembrolizumab
  • +7 more
  • (no location specified)
Feb 20, 2023

NSCLC Trial in Changsha (BEBT-109)

Completed
  • NSCLC
  • Changsha, Hunan, China
    Hunan Cancer hospital
Aug 20, 2023

A Chart Review Study of Adults With Advanced NSCLC

Not yet recruiting
  • Non-small Cell Lung Cancer (NSCLC)
    • (no location specified)
    Aug 1, 2022

    Locally Advanced or Metastatic NSCLC Trial in Seoul (Osimertinib 80 MG [Tagrisso])

    Completed
    • Locally Advanced or Metastatic NSCLC
    • Osimertinib 80 MG [Tagrisso]
    • Seoul, Korea, Republic of
      Seoul National University Hospital
    Sep 22, 2021

    Learn About Tests Looking forGene Mutation in Lung Cancer in

    Not yet recruiting
    • Non-small Cell Lung Cancer (NSCLC)
    • No Intervention
    • Beijing, China
      Department of Pathology, National Cancer Center/National Clinica
    Feb 24, 2023

    NSCLC Trial in Shanghai (Furmonertinib 240mg, Furmonertinib 160mg)

    Withdrawn
    • NSCLC
    • Furmonertinib 240mg
    • Furmonertinib 160mg
    • Shanghai, China
      Shanghai Chest hospital
    Oct 17, 2021

    Locally Advanced or Metastatic NSCLC, EGFR Exon20 Insertion Mutations Trial (JMT101, Osimertinib Mesylate Tablets)

    Not yet recruiting
    • Locally Advanced or Metastatic Non-Small Cell Lung Cancer
    • EGFR Exon20 Insertion Mutations
    • JMT101
    • Osimertinib Mesylate Tablets
    • (no location specified)
    Nov 12, 2021

    Non-small Cell Lung Cancer EGFR Exon 20 Insertion

    Recruiting
    • Non-small Cell Lung Cancer (NSCLC)
      • Cordoba, Andalucia, Spain
      • +14 more
      Nov 1, 2022

      NSCLC Trial in Amsterdam, Groningen, Maastricht (Afatinib, Cetuximab)

      Recruiting
      • Carcinoma, Non-Small-Cell Lung
      • Amsterdam, North-Holland, Netherlands
      • +3 more
      Oct 19, 2021

      NSCLC Trial in China (DZD9008)

      Active, not recruiting
      • Non-Small Cell Lung Cancer
      • Beijing, China
      • +32 more
      Jan 26, 2023

      NSCLC, Stage IV, NSCLC Stage IIIB, NSCLC, Stage IIIC Trial in Canada, Hong Kong, United States (tarloxotinib bromide)

      Terminated
      • NSCLC, Stage IV
      • +7 more
      • tarloxotinib bromide
      • Irvine, California
      • +13 more
      Nov 11, 2021

      Non Small Cell Lung Cancer, EGFR Exon 20 Mutation Trial in Worldwide (CLN-081)

      Recruiting
      • Non Small Cell Lung Cancer
      • EGFR Exon 20 Mutation
      • Duarte, California
      • +18 more
      Nov 11, 2022

      Osimertinib for Patients With Non-Small Cell Lung Cancer

      Not yet recruiting
      • Locally Advanced or Metastatic Non-Small Cell Lung Cancer
      • EGFR Exon20 Insertion Mutations
      • Baoding, China
      • +23 more
      Aug 23, 2022

      Metastatic NSCLC Trial (Amivantamab)

      Approved for marketing
      • Metastatic Non-Small Cell Lung Cancer
      • (no location specified)
      Jun 28, 2021

      NSCLC (NSCLC) Trial (TAK-788, Antidiarrheal prophylaxis)

      Withdrawn
      • Non-Small Cell Lung Cancer (NSCLC)
      • (no location specified)
      Dec 15, 2020

      Advanced/Metastatic NSCLC (NSCLC) Trial in China (YK-209A tablet, Pemetrexed+carboplatin/Cisplatin)

      Not yet recruiting
      • Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
      • Bengbu, Anhui, China
      • +51 more
      Mar 11, 2023

      NSCLC Trial in Worldwide (Poziotinib)

      Active, not recruiting
      • NSCLC
      • Phoenix, Arizona
      • +62 more
      Jan 27, 2023